Clinical Phase Equipment
-
Manufactured by Hemostemix Inc.based in CANADA
Hemostemix is currently conducting a randomized, double-blind, placebo-controlled Phase 2 clinical trial for patients with critical limb ischemia at sites in the Canada and United ...
-
Manufactured by Gesynta Pharma ABbased in SWEDEN
Gesynta Pharma’s drug candidate GS-073 is expected to enter clinical phase I in 2022. It is currently in the final stages of preclinical development. This project will be addressing an indication with high unmet need, which is separate from systemic ...
-
Manufactured by BCN Peptides S.A.based in SPAIN
in the manufacturing of peptides for all clinical phases, from pre-clinical to phase I, II, III and commercial stage. Our facility has been specially designed by BCN Peptides applying our expert know-how in Solid Phase Peptide Synthesis. Moreover since 2020 our site is in expansion with a new manufacturing plant ...
-
Manufactured by RapiGEN Inc.based in SOUTH KOREA
NS1 (non-structural protein 1) is a highly conserved glycoprotein that is essential for the viability of the Dengue virus and is produced both in membrane-associated and secretory forms by the virus. NS1 antigen is present at a high concentration in the blood of dengue virus-infected patients during the early clinical phase of the ...
-
by Verb Bioticsbased in USA
functions. We have achieved the formulation feasibility and cleared the regulatory hurdles associated with developing this new biotherapy. Continue our development plan to the clinical phase is the further step for this program. ...
-
Manufactured by Shanghai Henlius Biotech, Incbased in CHINA
HLX04-O, recombinant anti-VEGF humanised monoclonal antibody injection. It is indicated for wet age-related macular degeneration (wAMD). HLX04-O was granted Phase 3 clinical study approvals in Australia, the United States, Singapore and the EU countries such as Latvia, Hungary and Spanish. In April 2022, the first patient in Australia and ...
-
Manufactured by Gesynta Pharma ABbased in SWEDEN
GS-248 is Gesynta Pharma’s most advanced drug candidate, currently in clinical development as a potential treatment of systemic sclerosis. Recent clinical phase I data in healthy individuals show that GS-248 potently inhibits the production of PGE2 in a tolerable and safe manner, while increasing the observed levels of ...
-
Manufactured by Virometix AGbased in SWITZERLAND
and the only prophylaxis is a monoclonal Ab (palivizumab) restricted to high-risk pediatric patients. With V-306 Virometix offers a differentiated approach to RSV vaccine development. Our vaccine candidate – already in clinical phase I – demonstrates strong, durable, specific and protective immune responses, with minimal risk of ...
-
Manufactured by SiO2 Materials Sciencebased in USA
We provide a common drug contact surface starting at the research and pre-clinical drug development phases, through clinical trials, and on through to commercial ...
-
Manufactured by SiO2 Materials Sciencebased in USA
We provide a common drug contact surface starting at the research and pre-clinical drug development phases, through clinical trials, and on through to commercial ...
-
Manufactured by MitoImmune Therapeutics Inc.based in SOUTH KOREA
MIT-001 is expected to meet the medical need for oral mucositis for which there is no cure. It aims to be a first-in-class drug that can be used by both patients with head and neck cancer or hematological cancer with a high incidence and severity of oral mucositis as a side effect of chemoradiation ...
-
based in USA
STAR-OLZ is a 5-day transdermal patch in development for the treatment of chemotherapy induced nausea and vomiting (CINV). STAR-OLZ successfully completed Phase 1 human bioavailability studies and is now preparing to advance to a Phase 2 clinical trial. Starton Therapeutics Phase 2 TROPIC-I clinical study will be ...
-
Manufactured by CanaQuest Medical Corp.based in CANADA
Clinical testing on humans can only begin after a pre-clinical phase, involving laboratory studies (in vitro) and tests on animals, which has shown that the experimental drug is considered safe and effective. However, no animal is sufficiently similar to humans (even genetically modified ones) to make human testing unnecessary. For this ...
-
by Vivozon Inc.based in SOUTH KOREA
A multicenter, randomized, double-blind, parallel-group, placebo-controlled phase 3 clinical trial to evaluate the analgesic efficacy and safety of VVZ-149 injection in patients who have pain after laparoscopic ...
-
Manufactured by Lung Therapeutics, Inc.based in USA
A pleural effusion is defined by the build-up of fluid in the pleural cavity, predominantly resulting from pneumonia. A loculated pleural effusion (LPE) occurs when scar tissue forms in the pleural cavity, trapping the fluid and preventing drainage. Our lead compound, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue. We believe ...
-
based in USA
QTORIN™ rapamycin 3.9% is a novel targeted topical therapy being studied for Microcystic Lymphatic Malformations (Micro LM). Palvella is enrolling a phase 2 clinical study for people with Micro ...
-
Manufactured by PolyActiva Pty Ltd.based in AUSTRALIA
Being developed to reduce IOP caused by Open-Angle Glaucoma & Ocular Hypertension. Clinical Investigation Stage: Phase ...
-
Manufactured by Addex Therapeuticsbased in SWITZERLAND
mGlu2 NAM for the treatment of mild neurocognitive disorders, or mNCD. We are developing mGlu2 NAM as a novel orally available treatment for mNCD associated with Alzheimer’s disease, Parkinson’s disease and depressive disorders. The program is in clinical candidate selection phase and we expect to enter IND enabling studies early in ...
-
Manufactured by OSE Immunotherapeuticsbased in FRANCE
CoVepiT, a multi-target and multi-variant vaccine candidate against COVID-19. CoVepiT is a next-generation multi-target, multi-variant vaccine against SARS-CoV-2 in clinical Phase 1. The vaccine candidate was designed using optimized epitopes selected after screening more than 67,000 global SARS-CoV-2 genomes, as well as those of previous ...
-
Manufactured by Shanghai Henlius Biotech, Incbased in CHINA
HLX14, recombinant anti-RANKL human monoclonal antibody injection, a denosumab biosimilar. It is potentially indicated for the treatment of postmenopausal women with OP at high risk for fracture. First subject has been doesd in the international multi-centre phase 3 clinical trial in China for the treatment of postmenopausal osteoporosis in ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you